Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ribociclib + Endocrine Therapy in Premenopausal Advanced Breast Cancer
NCT02278120Phase 3Completed
- Sponsor
- Novartis
- Start
- Nov 2014
- Primary completion
- Aug 2017
- Modality
- Small Molecules
- Countries
- 30
01
Overview
Phase 3, randomised, double-blind trial in breast cancer comparing Ribociclib Arm with Placebo Arm (2 arms). Primary endpoint: Progression Free Survival at 29 months. Started Nov 2014; status: completed.
02
Drugs
ribociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02278120.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02278120.